Compare SSII & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSII | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | India | United States |
| Employees | 483 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 774.5M | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | SSII | XERS |
|---|---|---|
| Price | $3.96 | $6.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 36.1K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ N/A | $590.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $3.02 | $4.30 |
| 52 Week High | $11.87 | $10.08 |
| Indicator | SSII | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 50.83 |
| Support Level | $3.70 | $5.79 |
| Resistance Level | $5.14 | $6.41 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 42.24 | 31.49 |
SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.